Adding salt could be a surprisingly simple new strategy for making mRNA vaccines and gene therapies more effective, according to a study from the University of Houston's College of Pharmacy. Published in the journal Small, the research tackles a core problem in gene medicine: getting fragile therapeutic material to the right place inside cells. The team found that this common additive can help overcome one of the field's biggest obstacles.
For years, scientists have struggled with delivering genetic payloads efficiently to their intended targets within the body. The new approach offers a low-tech but potentially game-changing solution that avoids complex chemical modifications. The method's simplicity could make it easier to scale and manufacture treatments.
The findings suggest that salt alters how nanocarriers interact with cells, improving uptake of the therapeutic cargo. Researchers have not yet released exact performance data from the experiments, but the study provides a proof of concept. If validated, the technique might be applied to existing mRNA vaccine platforms or experimental gene therapies.
The team plans to continue testing the approach in animal models. The work could lower costs and accelerate development of next-generation treatments for diseases ranging from cancer to rare genetic disorders. No human trials have been announced.
The study's reliance on a single common additive raises questions about whether the effect holds across different cell types and delivery systems. Independent replication will be needed before the method can be considered a reliable clinical tool.